FDA says mifepristone review will continue into 2027

The FDA told a federal court it expects to finish a mifepristone safety study by mid-December and issue a report by March 2027, the Associated Press reports via STAT. Abortion opponents criticized the timetable. The filing announces a review schedule, rather than a new safety finding or change in access; the FDA has previously reaffirmed the drug’s safety and effectiveness.